Juuso Määttä

Juuso Määttä

Auto-generated profile, based on publicly available information

Juuso Määttä

Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
TSTanja Salomaa
Tanja Salomaa
TPToini Pemmari
Toini Pemmari
JMJuuso Määttä
Juuso Määttä
LKLaura Kummola
Laura Kummola
NSNiklas Tapio Salonen
Niklas Tapio Salonen
IJIlkka S. Junttila
Ilkka S. Junttila
Type 2 inflammation‒related cytokine IL-13 plays a protective role in experimental papilloma induction in mice. To understand the mechanisms by which IL-13 contributes to papilloma formation, we utilized Il13rα1-knockout (KO) mice in a widely used 7,12-dimethylbenz[a]anthracene/12-O-tetradecanoyl phorbol-13-acetate two-stage skin carcinogenesis protocol that mimics the development of squamous cell carcinoma. KO mice developed more papillomas and significantly faster than wild-type mice. Papilloma development reduced regulatory T cells in wild-type mice but substantially less in KO mice. In line with this, IL-2 and IL-10 levels decreased in wild-type mice but not in KO mice. Furthermore, systemic IL-5 and TSLP levels were elevated, whereas IL-22 was decreased during papilloma formation in the skin of KO mice. Polymorphonuclear myeloid‒derived suppressor cells were decreased in the KO mice at the early phase of papilloma induction. We show that IL-13Rα1 protects from papilloma development in chemically induced skin carcinogenesis, and our results provide further insights into the protective role of functional IL-4 and IL-13 signaling through type II IL-4 receptor in tumor development.